An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared on LinkedIn:
”Today, at the Late-Breaking Abstract Session at the 67th American Society of Hematology Annual Meeting and Exposition, we shared positive results from a Phase III trial in adults with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.
With a course of four once-monthly doses, our investigational therapy studied in this trial offers a promising alternative to chronic treatment.
ITP is a rare autoimmune condition where the immune system mistakenly destroys platelets, leading to prolonged bleeding, easy bruising and chronic fatigue.
This potential treatment is designed to target B cells, a key driver in ITP and other autoimmune diseases, through a dual mechanism of action.
Today’s results represent an important step forward in ITP and add to the growing body of evidence for this therapy, which is currently being studied across multiple B cell-driven conditions.
Thank you to all the patients, investigators, and teams involved in this research.”
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 4, 2026, 10:36Harprit Singh: Future – Ready Hospitals Will Have Apheresis Hubs, Not Just Dialysis Units
-
Apr 4, 2026, 09:21Moustafa Abdou: New Horizons in Hematology and Recent Drug Approvals
-
Apr 4, 2026, 09:13David McIntosh: From Western Dominance to LMIC Influence in Plasma Medicine with SK Plasma
-
Apr 4, 2026, 09:03Thomas Pincez: Mechanisms and Pathology of Immune Thrombocytopenia
-
Apr 4, 2026, 08:36Sylvain Perruche: Reactivating the Body Own Resolution Program in Inflammatory Disease
-
Apr 4, 2026, 08:27Daniel Pereira Monteiro: HbF Raised with HbC and HbA – What to Do Next?
-
Apr 4, 2026, 08:13Eoin McGrath: Common Language for Blood Transfer Across Organizations
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?